Methods of handling adhesive laminate patches. A first article, passed over a first supporting structure, includes disconnected adhesive laminate patches adhered to a first web, each patch being aligned over and adhered to a tab. A second web can be passed over a second supporting structure that is separated from the first supporting structure by a gap. The first article can be passed over the first supporting structure to lift a leading portion of a first tab and a first patch off of the first web together, such that the first tab facilitates transfer of the first patch across the gap. The first patch can then be adhered to the second web; and the second web can be advanced to transfer the first patch, and first tab, onto the second web to form a second article comprising patches aligned over tabs on the second web.

Methods, compositions, and devices for enhancing transdermal delivery of large agents.

A method for suppressing a plasma concentration of an asenapine metabolite includes applying to a subject a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer includes asenapine and/or a pharmaceutically acceptable salt thereof, and an adhesive base agent.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

Embodiments of stable topical compositions for administering fenoldopam (compound (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed for immediate or continued slow release administration, over prolonged periods of time with safe minimal systemic exposure of fenoldopam (reducing the risk for lowering blood pressure). The compositions include those compositions that increase the stability and skin absorption of the drug, particularly anhydrous semi-solid compositions and creams. This is accomplished by incorporating fenoldopam in soluble or dispersed form into semi-solid compositions like ointments or anhydrous gels that are not irritative. Embodiments of methods for using the topical compositions in the treatment of dermatological disorders including psoriasis, alopecia atopic dermatitis and vitiligo are disclosed.

##STR00001##

Transdermal patches and transdermally applyable pharmaceutical compositions containing an effective amount of at least one drug are disclosed. The at least one drug may be: (a) phenmetrazine; (b) 4-benzylpiperidine; (c) 3-flouroamphetamine; (d) a DA/NE releaser compound having formula (I): wherein each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 is independently hydrogen, a halogen, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted alkoxy group, and when one or more substituents is present on an alkyl group, an alkoxy group, or both, each substituent is independently a halogen; or (e) any combination thereof. Methods of making transdermal patches and transdermally applyable pharmaceutical compositions and methods of using transdermal patches and transdermally applyable pharmaceutical compositions are also disclosed.

##STR00001##

A method for producing an antibiotic-loaded transdermal patch including preparing a polymeric adhesive solution by dissolving a polymeric mixture in a solvent, preparing a plurality of antibiotic-loaded solid lipid nanoparticles (SLNs), forming a patch formulation by mixing the plurality of antibiotic-loaded SLNs and the polymeric adhesive solution, and forming a layer of the patch formulation on a substrate.

The present invention provides the following compounds having anti-viral activity. ##STR00001## A.sup.1 is CR.sup.1AR.sup.1B, S or O; A.sup.2 is CR.sup.2AR.sup.2B, S or O; A.sup.3 is CR.sup.3AR.sup.3B, S or O; A.sup.4 is CR.sup.4AR.sup.4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A.sup.1, A.sup.2, A.sup.3, A.sup.4, nitrogen atom adjacent to A.sup.1 and carbon atom adjacent to A.sup.1, is 1 or 2; R.sup.1A and R.sup.1B are each independently hydrogen, halogen, alkyl, or the like; R.sup.2A and R.sup.2B are each independently hydrogen, halogen, alkyl, or the like; R.sup.3A and R.sup.3B are each independently hydrogen, halogen, alkyl, or the like; R.sup.4A and R.sup.4B are each independently hydrogen, halogen, alkyl, or the like; R.sup.3A and R.sup.3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH.sub.2, S or O; R.sup.1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

The present invention relates to a mucoadhesive layer, preferably mucoadhesive buccal layer, comprising a non-nanoparticulate macrolide. Furthermore, the present invention relates to a mucoadhesive film, preferably mucoadhesive buccal film, comprising a mucoadhesive layer comprising a non-nanoparticulate macrolide, and further comprising a backing layer. The present invention also relates to a mucoadhesive film, preferably mucoadhesive buccal film, comprising a mucoadhesive layer, a backing layer, and an intermediate layer. The present invention further relates to a mucoadhesive layer or mucoadhesive film for use as a medicament and for use in preventing and/or treating transplant rejection. Moreover, the present invention relates to a method of preparing a mucoadhesive film.